trigeminal neuralgia (tn) therapeutics – pipeline assessment

1. Trigeminal Neuralgia (TN) Therapeutics - PipelineAssessment and Market Forecasts to 2017

2. Trigeminal Neuralgia Therapeutics Market is Forecast to Show Static Growth to 2017 GlobalData estimated the trigeminal neuralgia (TN) therapeutics market to be worth $83.53m in 2010 and forecasts it to grow at a Compound annual growth rate (CAGR) of 2.7% to reach $100.62m in 2017. The low growth is because TN therapeutics market is dominated by generics. The lower cost of generics brings down the overall market value. The TN therapeutics pipeline does not have any industry sponsored molecules in clinical development. Current Competition in the TN Market is Weak GlobalData’s analysis suggested that the current competition in the TN therapeutics market is weak. The market has only one generic product, Tegretol (carbamazepine), approved by the FDA (Food and Drug Administration) and the EMEA (European Medicines Agency) for the treatment of TN. Most of the other products are prescribed off-label by physicians, except Lyrica (pregabalin), are also generics that offer partial relief from pain in the long run. Thus, the current treatment options are unable to completely serve the market’s unmet need, which clearly signifies that the current competition in the TN therapeutics market is weak. Weak TN Pipeline unable to satisfy the unmet need The TN therapeutics pipeline is weak as it has no industry-sponsored molecules in clinical development. The pipeline consists of only one molecule, Lamictal (lamotrigine), in Phase III of development.

3. High Unmet Need in the TN Therapeutics Market The TN therapeutics market has high unmet need, which implies that the market is not well served by the current products. The TN therapeutics market has only one drug, carbamazepine, approved by the FDA and EMEA to treat TN. Carbamazepine is an old generic drug, approved in 1962, which provides complete or partial relief to as many as 80% of patients in the short term. However, only 56% respond in the long-term. It has many side effects, such as dizziness, ataxia and sedation (mental dullness), allergic rash, myelosuppression, hepatotoxicity, lymphadenopathy, systemic lupus erythematosus, Stevens– Johnson syndrome and aplastic anaemia. This makes it harder to treat elderly patients, who are more likely to have TN. The other drugs prescribed for the treatment of TN are mostly off-label generics which include Trileptal (oxcarbazepine), Dilantin (phenytoin), Neurontin (gabapentin), Lioresal (baclofen), lamotrigine and others. Lyrica is also effective in reducing pain by over 50% in some patients. But these drugs do not offer long term relief from pain, and offer limited symptomatic treatment, which leaves high unmet need in the TN therapeutics market. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Depression-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report

4. GlobalData, the industry analysis specialist, has released its new report, “Trigeminal Neuralgia (TN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global TN market. The report identifies the key trends shaping and driving the global TN market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global TN sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782